A recent randomized controlled trial also correlated the amelioration of hepatic steatosis and necroinflammation in NASH patients with the enhancement of adiponectin levels and the decrease of visceral-to-subcutaneous fat ratio after pioglitazone (45 mg/d for 6-months) treatment [143]. This evidence concerns the gene ADIPOQ and fatty liver disease.